SE0303526D0 - Chemotherapeutic agents - Google Patents

Chemotherapeutic agents

Info

Publication number
SE0303526D0
SE0303526D0 SE0303526A SE0303526A SE0303526D0 SE 0303526 D0 SE0303526 D0 SE 0303526D0 SE 0303526 A SE0303526 A SE 0303526A SE 0303526 A SE0303526 A SE 0303526A SE 0303526 D0 SE0303526 D0 SE 0303526D0
Authority
SE
Sweden
Prior art keywords
tetrahydrofolate
pharmaceutical composition
chemotherapeutic agents
methylene
cancer
Prior art date
Application number
SE0303526A
Other languages
English (en)
Inventor
Bengt Gustavsson
Goeran Carlsson
Original Assignee
Biofol Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofol Ab filed Critical Biofol Ab
Priority to SE0303526A priority Critical patent/SE0303526D0/sv
Publication of SE0303526D0 publication Critical patent/SE0303526D0/sv
Priority to ES04766997T priority patent/ES2349929T3/es
Priority to AT04809128T priority patent/ATE476996T1/de
Priority to US10/583,508 priority patent/US20070249613A1/en
Priority to JP2006546912A priority patent/JP5043441B2/ja
Priority to SI200431528T priority patent/SI1699462T1/sl
Priority to PT04809128T priority patent/PT1699462E/pt
Priority to DE200460028654 priority patent/DE602004028654D1/de
Priority to ES04809128T priority patent/ES2349930T3/es
Priority to EP04809128A priority patent/EP1699462B1/en
Priority to CA 2550298 priority patent/CA2550298C/en
Priority to DK04809128T priority patent/DK1699462T3/da
Priority to PCT/SE2004/001955 priority patent/WO2005060973A1/en
Priority to PL04809128T priority patent/PL1699462T3/pl
Priority to US12/805,287 priority patent/US9138435B2/en
Priority to CY20101100964T priority patent/CY1110859T1/el
Priority to JP2011249060A priority patent/JP2012087130A/ja
Priority to US14/811,905 priority patent/US9585888B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
SE0303526A 2003-09-29 2003-12-22 Chemotherapeutic agents SE0303526D0 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE0303526A SE0303526D0 (sv) 2003-12-22 2003-12-22 Chemotherapeutic agents
ES04766997T ES2349929T3 (es) 2003-09-29 2004-09-24 Material cristalino microporoso de naturaleza zeolítica, zeolita itq-28, procedimiento de preparación y uso.
PL04809128T PL1699462T3 (pl) 2003-12-22 2004-12-22 Połączenie [6R]-metylenotetrahydrofolanu z antyfolanami ukierunkowanymi na wiele celów do zmniejszania ich toksyczności podczas leczenia raka
ES04809128T ES2349930T3 (es) 2003-12-22 2004-12-22 Combinación de [6r]-metilen-tetrahidrofolato con anti-folatos multidiana para reducir su toxicidad mientras que se trata el cáncer.
EP04809128A EP1699462B1 (en) 2003-12-22 2004-12-22 Combination of [6R]-methylenetetrahydrofolate with multi-targeting antifolates to reduce their toxicity while treating cancer
JP2006546912A JP5043441B2 (ja) 2003-12-22 2004-12-22 毒性の減少されたマルチターゲティングフォレート拮抗薬
SI200431528T SI1699462T1 (sl) 2003-12-22 2004-12-22 Kombinacija (6R)-metilen-tetrahidrofolata z večtračnimi antifolati za zmanjšanje njihove toksičnosti pri zdravljenju raka
PT04809128T PT1699462E (pt) 2003-12-22 2004-12-22 Combinação de tetra-hidrofolato de [6r]-metileno com antifolatos destinados a vários alvos para reduzir a toxicidade no tratamento do cancro
DE200460028654 DE602004028654D1 (de) 2003-12-22 2004-12-22 Kombination von Ä6RÜ-Methylenetetrahydrofolat mit Multitarget-Antifolaten um deren Toxizität zu verringern während der Behandlung von Krebs
AT04809128T ATE476996T1 (de) 2003-12-22 2004-12-22 Kombination von ä6rü-methylenetetrahydrofolat mit multitarget-antifolaten um deren toxizität zu verringern während der behandlung von krebs
US10/583,508 US20070249613A1 (en) 2003-12-22 2004-12-22 Reduction of Toxicity of Multi-Targeting Antifolates
CA 2550298 CA2550298C (en) 2003-12-22 2004-12-22 Reduction of toxicity of multi-targeting antifolates
DK04809128T DK1699462T3 (da) 2003-12-22 2004-12-22 Kombination af [6R]-methylentetrahydrofolat med multitarget-antifolater med henblik på at mindske deres toxicitet ved cancerbehandling
PCT/SE2004/001955 WO2005060973A1 (en) 2003-12-22 2004-12-22 Reduction of toxicity of multi-targeting antifolates
US12/805,287 US9138435B2 (en) 2003-12-22 2010-07-22 Reduction of toxicity of multi-targeting antifolates
CY20101100964T CY1110859T1 (el) 2003-12-22 2010-10-25 Συνδυασμος [6r]-meθyλenotetpayδpοφολikoy με πολυ-στοχοθετικα αντιφολικα για να μειωνεται τοξικοτητα αυτων ενω θεραπευεται καρκινος
JP2011249060A JP2012087130A (ja) 2003-12-22 2011-11-14 毒性の減少されたマルチターゲティングフォレート拮抗薬
US14/811,905 US9585888B2 (en) 2003-12-22 2015-07-29 Reduction of toxicity of multi-targeting antifolates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303526A SE0303526D0 (sv) 2003-12-22 2003-12-22 Chemotherapeutic agents

Publications (1)

Publication Number Publication Date
SE0303526D0 true SE0303526D0 (sv) 2003-12-22

Family

ID=30768841

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0303526A SE0303526D0 (sv) 2003-09-29 2003-12-22 Chemotherapeutic agents

Country Status (14)

Country Link
US (3) US20070249613A1 (sv)
EP (1) EP1699462B1 (sv)
JP (2) JP5043441B2 (sv)
AT (1) ATE476996T1 (sv)
CA (1) CA2550298C (sv)
CY (1) CY1110859T1 (sv)
DE (1) DE602004028654D1 (sv)
DK (1) DK1699462T3 (sv)
ES (2) ES2349929T3 (sv)
PL (1) PL1699462T3 (sv)
PT (1) PT1699462E (sv)
SE (1) SE0303526D0 (sv)
SI (1) SI1699462T1 (sv)
WO (1) WO2005060973A1 (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303526D0 (sv) * 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
EP2617421A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
EP2617422A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
PL2837632T3 (pl) * 2012-04-13 2017-01-31 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
NL2019147B1 (en) 2017-06-29 2019-01-14 D O R C Dutch Ophthalmic Res Center International B V A foot pedal control unit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) * 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CA2082811C (en) * 1990-05-11 2004-11-16 Colin P. Spears 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6921667B2 (en) * 2003-03-07 2005-07-26 Prometheus Laboratories, Inc. Methods for direct detection of individual methotrexate metabolites
SE0303526D0 (sv) 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents

Also Published As

Publication number Publication date
US20150328218A1 (en) 2015-11-19
CA2550298C (en) 2013-05-28
US9138435B2 (en) 2015-09-22
DK1699462T3 (da) 2010-11-08
US20070249613A1 (en) 2007-10-25
JP5043441B2 (ja) 2012-10-10
DE602004028654D1 (de) 2010-09-23
PT1699462E (pt) 2010-11-05
ES2349930T3 (es) 2011-01-13
ES2349929T3 (es) 2011-01-13
WO2005060973A1 (en) 2005-07-07
PL1699462T3 (pl) 2011-04-29
CA2550298A1 (en) 2005-07-07
EP1699462A1 (en) 2006-09-13
ATE476996T1 (de) 2010-08-15
JP2012087130A (ja) 2012-05-10
EP1699462B1 (en) 2010-08-11
SI1699462T1 (sl) 2010-12-31
CY1110859T1 (el) 2015-06-10
US20100311762A1 (en) 2010-12-09
JP2007515482A (ja) 2007-06-14
US9585888B2 (en) 2017-03-07

Similar Documents

Publication Publication Date Title
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
HK1096392A1 (en) Substituted heterocycles
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
NO20070782L (no) Tetrapeptidanaloger.
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
GEP20115231B (en) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones
WO2005105094A3 (en) Cancer treatment method
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
MXPA05012894A (es) Benzofuranos 3-sustituidos como agentes terapeuticos.
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
NO20024076L (no) Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer
DK1390371T3 (da) Oxazolo- og furopyrimidiner samt deres anvendelse i lægemidler mod tumorer
CY1110859T1 (el) Συνδυασμος [6r]-meθyλenotetpayδpοφολikoy με πολυ-στοχοθετικα αντιφολικα για να μειωνεται τοξικοτητα αυτων ενω θεραπευεται καρκινος
IL183481A0 (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
WO2005000204A3 (en) Pancreatic cancer treatment
SE0300457D0 (sv) Novel compounds
DE602005014087D1 (de) 7h-pyrrolopyrimidinderivate
HK1086493A1 (en) Treatment of proliferative diseases with epothilone derivatives and radiation
IL174365A (en) Bravatoxin Polyether Compounds, Pharmaceutical Formulations and the Use of Drug Preparation
WO2004091506A3 (en) Taxane-based compositions and methods of use
WO2004026319A3 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
HUP0302629A2 (hu) Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére